SAN FRANCISCO, April 06, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in MiMedx Group, Inc. (NASDAQ:MDXG) of the April 25, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired securities of MiMedx between March 7, 2013 and February 21, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MDXG
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On February 20, 2018, MiMedx postponed release of its fourth quarter and fiscal year 2017 financial results. Defendants explained “[t]he Audit Committee of MiMedx’s Board of Directors has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts[.]”
This news drove the price of MiMedx shares down $5.72, or nearly 40%, to close at $8.75 on February 20, 2018.
Then, Reuters reported federal authorities are investigating whether MiMedx overcharged the government for its tissue-repair products and whether it improperly booked sales of products that hadn’t been ordered, a practice known as channel stuffing.
“We’re focused on Defendants’ previous denials of improper accounting that, if false, damaged investors and on whether MiMedx submitted false claims to the Federal government,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MiMedx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000


Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Telegram Restored on Apple App Store After Temporary Removal
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 



